 | Up a level |
Journal Article
Bloch, W., Baumann, F., Zimmer, P., Grischke, E-M, Fasching, P. A., Decker, T., Uleer, C., Schneeweiss, A., Salat, C., Wimberger, P., Mundhenke, C., Foerster, F., Kluth-Pepper, B., Schubert, J., Tesch, H., Schuetz, F., Lueftner, D. and Jackisch, C. (2016). Impact of physical activity/exercise on adverse events and quality of life during treatment with everolimus and exemestane for ER plus women - Results of the 3rd interim analysis of BRAWO. Cancer Res., 76. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Degenhardt, T., Gluz, O., Thomssen, C., Vetter, M., Kates, R., Warm, M., Shak, S., Augustin, D., Kusche, M., Untch, M., Paepke, S., Uleer, C., Duennebacke, J., Nitz, U. and Harbeck, N. (2010). Risk Group Selection in Primary Breast Cancer According to ASCO Recommended Biomarkers Onkotype DX and uPA/PAI-1: First Experience from Prospective Multicenter WSG Plan B Trial. Cancer Res., 70. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Fasching, P. A., Link, T., Hauke, J., Seither, F., Jackisch, C., Klare, P., Schmatloch, S., Hanusch, C., Huober, J., Stefek, A., Seiler, S., Schmitt, W. D., Uleer, C., Doering, G., Rhiem, K., Schneeweiss, A., Engels, K., Denkert, C., Schmutzler, R. K., Hahnen, E., Untch, M., Burchardi, N., Blohmer, J-U and Loibl, S. (2021). Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann. Oncol., 32 (1). S. 49 - 58. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Giuz, O., Kreipe, H., Degenhardt, T., Kates, R., Christgen, M., Liedtke, C., Shak, S., Clemens, M., Markmann, S., Uleer, C., Augustin, D., Thomssen, C., Nitz, U. and Harbeck, N. (2011). Prospective Comparison of Risk Assessment Tools in Early Breast Cancer (Recurrence Score, uPA/PAI-1, Central Grade, and Luminal Subtypes): Final Correlation Analysis from the Phase III WSG-Plan B Trial. Cancer Res., 71. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Gluz, O., Hofmann, D., Von Schumann, R., Kates, R., Clemens, M., Salem, M., Reimer, T., Liedtke, B., Aktas, B., Stefek, A., Pollmanns, A., Lorenz-Salehi, F., Uleer, C., Krabisch, P., Augustin, D., Harbeck, N. and Nitz, U. (2014). Febrile neutropenia (FN) and infections under adjuvant chemotherapy of breast cancer with 6 x TC vs. 4 x EC-4 x Doc: Toxicity data of the WSG planB trial. Oncol. Res. Treat., 37. S. 14 - 16. BASEL: KARGER. ISSN 2296-5262
Gluz, O., Kreipe, H. H., Kates, R. E., Christgen, M., Liedtke, C., Shak, S., Clemens, M., Salem, M., Liedtke, B., Aktas, B., Markmann, S., Uleer, C., Augustin, D., Thomssen, C., Nitz, U. and Harbeck, N. (2012). Prospective comparison of Recurrence Score and different definitions of luminal subtypes by central pathology assessment of single markers in early breast cancer: results from the phase III WSG-planB Trial. Cancer Res., 72. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Gluz, O., Nitz, U., Christgen, M., Malter, W., Clemens, M., Reimer, T., Nuding, B., Aktas, B., Stefek, A., Ppllmanns, A., Lorenz-Salehi, F., Uleer, C., Krabisch, P., Kuemmel, S., Liedtke, C., Shak, S., Kates, R., Wurstlein, R., Kreipe, H. H. and Harbeck, N. (2017). Prognostic impact of recurrence score (RS), grade/Ki67 central pathological review, and acycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2-early breast cancer (EBC): WSG PlanB trial results. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Hauke, J., Ernst, C., Fasching, P. A., Jackisch, C., Seither, F., Klare, P., Rhiem, K. E., Schmatloch, S., Huober, J., Stefek, A., Seiler, S., Uleer, C., Doering, G., Schneeweiss, A., Denkert, C., Untch, M., Blohmer, J-U., Schmutzler, R. K., Loibl, S. and Hahnen, E. (2020). Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332). Ann. Oncol., 31. S. S313 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Lueftner, D., Grischke, E. M., Fasching, P., Decker, T., Schneeweiss, A., Uleer, C., Foerster, F., Wimberger, P., Kluth-Pepper, B., Schubert, J., Bloch, W., Tesch, H., Schuetz, F. and Jackisch, C. (2015). Disease characteristics of subgroup patients treated with everolimus plus exemestane for < 12 months, >= 12 to < 18months, and >= 18 months - Results of the 3rd interim analysis of the non-interventional trial BRAWO. Eur. J. Cancer, 51. S. S288 - 2. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Nitz, U., Gluz, O., Oberhoff, C., Reimer, T., Schumacher, C., Hackmann, J., Warm, M., Uleer, C., Runde, V., Kuemmel, S., Zuna, I. and Harbeck, N. (2011). Adjuvant Chemotherapy with or without Darbepoetin alpha in Node-Positive Breast Cancer: Survival and Quality of Life Analysis from the Prospective Randomized WSG ARA Plus Trial. Cancer Res., 71. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Nitz, U., Gluz, O., Zuna, I., Oberhoff, C., Reimer, T., Schumacher, C., Hackmann, J., Warm, M., Uleer, C., Runde, V., Duennebacke, J., Belzl, N., Augustin, D., Kates, R. E. and Harbeck, N. (2014). Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer. Ann. Oncol., 25 (1). S. 75 - 82. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Nitz, Ulrike, Gluz, Oleg, Clemens, Michael, Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kuemmel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald E., Kreipe, Hans H., Harbeck, Nadia, Ackermann, S., Aktas, B., Augustin, D., Baake, G., Baumann, K., Berger, R., Bettscheider, J., Bischoff, J., Clemens, M., Deryal, M., Dubbers, H., Duchting, D., Dunnebacke, J., Fett, W., Fietz, T., Fischer, H., Forner, M., Forstbauer, H., Freese, K., Geberth, M., Glados, M., Gnauert, K., Goette, O., Gohring, U., Goppinger, A., Grafe, A., Hackenberg, R., Hackmann, J., Hellriegel, M., Heyl, V., Hoestermann, C., Hoffmann, G., Hofmann, M., Hucke, J., Jackisch, C., Jungberg, P., Just, M., Kahl, C., Klare, P., Kogel, M., Kohls, A., Amrawy, B. Konigs-El, Konnecke, P., Krabisch, P., Kraudelt, S., Kremers, S., Kummel, S., Kurbacher, C., Kusche, J., Liedtke, B., Liedtke, C., Link, H., Lorenz, R., Salehi, F. Lorenz, Lubbe, K., Malter, W., Melekian, B., Mobus, V., Montenarh, M., Mueller, V., Mundhenke, C., Niederle, N., Nitz, U., Noesselt, T., Oberhoff, C., Paas, L., Paepke, S., Pollmanns, A., Reichert, D., Reimer, T., Romann, D., Ruhland, T., Runde, V., Salem, M., Schlosser, A., Schneider, A., Schrader, I., Schulz, H., Schumacher, C., Schwickerath, J., Soling, U., Stauder, H., Stefek, A., Steinmetz, T., Stickeler, E., Terhaag, J., Thomssen, C., Tome, O., Uleer, C., Warm, M., Wachsmann, G., Wacker, J., Wiebringhaus, H., Wiest, W., Wolfgarten, M., Nitz, U., Christgen, H., Kreipe, H., Buehne, C., Gluz, O., Hansen, K., Hofmann, D., Kates, R., Mangold, M., Mathissen, M., Raeth, P., Renner, I., Reiser, I., Schumacher, J., Staedele, M. and Walter-Kirst, R. (2019). West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. J. Clin. Oncol., 37 (10). S. 799 - 811. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Schuetz, F., Grischke, E-M, Decker, T., Uleer, C., Schneeweiss, A., Salat, C., Wimberger, P., Mundhenke, C., Foerster, F., Kluth-Pepper, B., Schubert, J., Bloch, W., Tesch, H., Jackisch, C., Idiftner, D. and Fasching, P. A. (2016). Stomatitis in patients treated with everolimus and exemestane - Results of the 3rd interim analysis of the non-interventional trial BRAWO. Cancer Res., 76. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Tesch, H., Grischke, E-M, Fasching, P., Decker, T., Uleer, C., Schneeweiss, A., Foerster, F., Wimberger, P., Kluth-Pepper, B., Schubert, J., Bloch, W., Jackisch, C., Schuetz, F. and Lueftner, D. (2015). Results of the 3rd interim analysis of BRAWO - breast cancer treatment with everolimus and exemestane for ER plus women. Oncol. Res. Treat., 38. S. 252 - 254. BASEL: KARGER. ISSN 2296-5262
Tesch, H., Grischke, E-M, Fasching, P. A., Decker, T., Uleer, C., Schneeweiss, A., Salat, C., Wimberger, P., Mundhenke, C., Foerster, F., Kluth-Pepper, B., Schubert, J., Bloch, W., Jackisch, C., Schuetz, F. and Lueftner, D. (2016). Results of the 3rd interim analysis of the non-interventional trial BRAWO - Subanalysis of patients < 70 years and >= 70 years. Cancer Res., 76. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445